Pharmac is seeking feedback on a rule change that could affect child cancer patients.
Under the current system, any medicine for pediatric cancer is automatically funded without a Pharmac assessment.
But the rule has raised issues about fairness for other serious diseases, so it is being reviewed.
Pharmac chief executive Sarah Fitt spoke to Corin Dann.
